ACADIA Pharmaceuticals Inc.
ACADNASDAQHealthcare● Active
$21.70
+$0.14(+0.65%)
Market Cap$3.7B
P/E Ratio—
52W High$28.35
52W Low$19.69
ACADIA Pharmaceuticals Inc. (ACAD) · Cash Flow
Annual, quarterly, or TTM views · SEC 10-K & 10-Q via FMP · adjust period and M/B/T below.
FMP · ACAD · as of 2026-06-10
Financial statements
Operating CF · CapEx · Free Cash Flow
| Breakdown | 2025-12 | 2024-12 | 2023-12 | 2022-12 | 2021-12 |
|---|---|---|---|---|---|
| Operating Activities | |||||
| Net Income | $0.39B | $0.23B | ($0.06B) | ($0.22B) | ($0.17B) |
| Depreciation & Amort. | $0.01B | $0.02B | $0.01B | $0.00B | $0.00B |
| Stock-Based Comp. | $0.00B | $0.07B | $0.07B | $0.07B | $0.06B |
| Change in Working Capital | ($0.09B) | $0.00B | $0.02B | $0.04B | ($0.02B) |
| Net Cash from Operations | $0.11B | $0.16B | $0.02B | ($0.11B) | ($0.13B) |
| Investing Activities | |||||
| Capital Expenditure | ($0.00B) | ($0.00B) | ($0.04B) | $0.00B | ($0.00B) |
| Purchases of Investments | ($0.69B) | ($0.51B) | ($0.37B) | ($0.36B) | ($0.49B) |
| Sales of Investments | $0.49B | $0.33B | $0.44B | $0.44B | $0.42B |
| Net Cash from Investing | ($0.30B) | ($0.03B) | $0.03B | $0.07B | ($0.07B) |
| Financing Activities | |||||
| Common Stock Repurchased | $0.00B | $0.00B | $0.00B | $0.00B | $0.00B |
| Dividends Paid | $0.00B | $0.00B | $0.00B | $0.00B | $0.00B |
| Debt Issued / Repaid | $0.00B | $0.00B | $0.00B | $0.00B | $0.00B |
| Net Cash from Financing | $0.05B | $0.01B | $0.03B | $0.01B | $0.02B |
| Free Cash Flow | |||||
| Free Cash Flow | $0.11B | $0.16B | ($0.02B) | ($0.11B) | ($0.13B) |
| FCF Margin %(computed) | 9.81% | 16.41% | -3.21% | -22.05% | -26.19% |
Data source: Financial Modeling Prep · Last updated: 2026-06-10 · USD · B
Explore more ACADIA Pharmaceuticals Inc. data
About ACADIA Pharmaceuticals Inc. (ACAD) Cash Flow Statement
ACADIA Pharmaceuticals Inc. generated operating cash flow of $0.11B and free cash flow of $0.11B for 2025 — a FCF margin of 9.81%. Capital expenditure was ($0.00B).
Frequently asked questions
ACAD · 4 questionsACADIA Pharmaceuticals Inc. generated free cash flow of $0.11B for 2025, down 33.1% year-over-year.
ACAD free cash flowFCF margincash flow yield
· Source: FMP /stable/cash-flow-statement · SEC EDGAR Form 10-K & 10-Q · As of 2026-06-10